SEB will exclusively provide processing and storage services and could partner on future research.

Cryo-Cell granted Chinese company S-Evans Biosciences (SEB) an exclusive license to market and manufacture its C’elle menstrual stem cell technology including processing and storage of menstrual stem cells throughout mainland China. The deal also allows SEB to conduct research using this platform to identify potential therapeutic applications for a range of diseases.

The C’elle service is based on Cryo-Cell’s patent-pending IP portfolio and was introduced in November 2007 as a service that allows women to collect and cryopreserve menstrual flow containing undifferentiated adult stem cells for future potential utilization by the donor or possibly first-degree relatives in a manner similar to umbilical cord blood stem cells.

The agreement provides Cryo-Cell future royalty fees from the processing and annual storage of menstrual stem cells.

SEB is located near Shanghai in Hangzhou, Zhejiang Province, People’s Republic of China. It reportedly collaborates with several local institutions, hospitals, and Zhejiang-California International Nanosystems Institute (ZCNI). ZCNI is a Sino-U.S. institute for biomedicine and nanotechnology research located on Zhejiang University campus.

Previous articleMergers and Acquisitions—The New IPO
Next articleMassachusetts General Hospital Cancer Center to Use the Helicos™ Genetic Analysis System